Prognostic effect of mean platelet volume in patients with coronary artery disease

Summary

Large platelets with high haemostatic activity may lead to increased platelet aggregation.. Mean platelet volume (MPV), an indicator of platelet reactivity, may emerge as a prognostic marker in patients with coronary artery disease (CAD). It was the objective of this study to conduct a systematic review and meta-analysis to assess prognostic effects of MPV on cardiovascular events (CVE) in CAD patients. We searched MEDLINE and SCOPUS from inception to January 2, 2014. All studies that reported MPV and the incidence of cardiovascular events in CAD patients were included. Two reviewers independently extracted the data. A random-effects model was applied for pooling the mean difference of MPV between patients with vs without CVE. Among 30 eligible studies, eight studies reported mean difference of MPV between CVE groups, 11 studies reported MPV dichotomous into high vs low MPV groups, and 11 studies reported both. The pooled mean difference was 0.69 fL (95 %CI = 0.36, 1.01), i. e. patients with CVE had a MPV about 0.69 fL higher than non-CVE. Patients with higher MPV were about 12 % more likely to die than patients with lower MPV (RR 1.12; 95 %CI = 1.02–1.24). However, pooling these effects was based on high heterogeneity and the source of heterogeneity could not be identified. This might be explained by many differences among included studies (e. g. study population, outcomes of interest, analysate, time between blood collection and MPV analysis, etc). These findings suggest that MPV may be a useful prognostic marker in patients with CAD.

Keywords

Mean platelet volume - coronary artery disease - cardiovascular diseases - prognosis - meta-analysis

• References

• 1 Eagle KA, Lim MJ, Dabbous OH. et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. J Am Med Assoc 2004; 291: 2727-2733.
• 2 Granger CB, Goldberg RJ, Dabbous O. et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003; 163: 2345-2353.
• 3 Antman EM, Cohen M, Bernink PJ. et al. The TIMI risk score for unstable angina/ non-ST elevation MI: A method for prognostication and therapeutic decision making. J Am Med Assoc 2000; 284: 835-842.
• 4 Boersma E, Pieper KS, Steyerberg EW. et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557-2567.
• 5 Gale CP, Manda SO, Weston CF. et al. Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database. Heart 2009; 95: 221-227.
• 6 Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364: 1746-1760.
• 7 Jneid H, Anderson JL, Wright RS. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875-910.
• 8 Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
• 9 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: 485-510.
• 10 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin „resistance“ and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
• 11 Sofi F, Marcucci R, Gori AM. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. J Thromb Haemost 2010; 103: 841-848.
• 12 Jakubowski JA, Adler B, Thompson CB. et al. Influence of platelet volume on the ability of prostacyclin to inhibit platelet aggregation and the release reaction. J Lab Clin Med 1985; 105: 271-276.
• 13 Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996; 07: 157-161.
• 14 Tekbas E, Kara AF, Ariturk Z. et al. Mean platelet volume in predicting short- and long-term morbidity and mortality in patients with or without ST-segment elevation myocardial infarction. Scand J Clin Lab Invest 2011; 71: 613-619.
• 15 Dogan A, Aksoy F, Icli A. et al. Mean platelet volume is associated with culprit lesion severity and cardiac events in acute coronary syndromes without ST elevation. Blood Coagul Fibrinolysis 2012; 23: 324-330.
• 16 Varol E, Uysal BA, Dogan A. et al. Mean platelet volume has a prognostic value in patients with coronary artery ectasia. Clin Appl Thromb Hemost 2012; 18: 387-392.
• 17 Kalay N, Dogdu O, Koc F. et al. Hematologic parameters and angiographic progression of coronary atherosclerosis. Angiology 2012; 63: 213-217.
• 18 Fabregat-Andres OC, Ferrando-Beltran A, Bochard-Villanueva M. et al. Mean platelet volume is associated with infarct size and microvascular obstruction estimated by cardiac magnetic resonance in ST segment elevation myocardial infarction. Blood Coagul Fibrinolysis 2013; 24: 424-427.
• 19 Verdoia MC, Barbieri C, Schaffer L. et al. Mean platelet volume and the risk of periprocedural myocardial infarction in patients undergoing coronary angioplasty. Atherosclerosis 2013; 228: 136-141.
• 20 The New-castle-Ottawa Scale (NOS) for asseessing the quality of nonrandomised studies in meta-analyses. Ontario, Canada: The Ottawa Hospital Foundation; 2014. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
• 21 Burr ML, Holliday RM, Fehily AM. et al. Haematological prognostic indices after myocardial infarction: Evidence from the diet and reinfarction trial (DART). Eur Heart J 1992; 13: 166-170.
• 22 Cesari FM, Gori R, Caporale AM. et al. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients: Insights from the AMI-florence 2 study. J Thromb Haemost 2013; 109: 846-853.
• 23 Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 1409-1411.
• 24 Norgaz T, Hobikoglu G, Aksu H. et al. The relationship between preprocedural platelet size and subsequent in-stent restenosis. Acta Cardiol 2004; 59: 391-395.
• 25 Smyth DW, Martin JF, Michalis L. et al. Influence of platelet size before coronary angioplasty on subsequent restenosis. Eur J Clin Invest 1993; 23: 361-367.
• 26 Susam I, Yaylali YT, Ate A. et al. Relationship of admission mean platelet volume with no-reflow in acute myocardial infarction treated with fibrinolysis. Anatol J Clin Invest 2011; 05: 74-77.
• 27 Terres W, Lund GK, Hubner A. et al. Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 1995; 130: 711-716.
• 28 Aksu H, Ozer O, Unal H. et al. Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes. Blood Coagul Fibrinolysis 2009; 20: 686-693.
• 29 Azab B, Torbey E, Singh J. et al. Mean platelet volume/platelet count ratio as a predictor of long-term mortality after non-ST-elevation myocardial infarction. Platelets 2011; 22: 557-566.
• 30 Celik T, Kaya MG, Akpek M. et al. Predictive Value of Admission Platelet Volume Indices for In-hospital Major Adverse Cardiovascular Events in Acute ST-Segment Elevation Myocardial Infarction. Angiology 2015; 66: 155-162.
• 31 Choi SWC, Kim DH, Ku HW. et al. Clinical outcome prediction from mean platelet volume in patients undergoing percutaneous coronary intervention in Korean cohort: Implications of more simple and useful test than platelet function testing. Platelets 2014; 25: 322-327.
• 32 Elbasan Z, Gur M, Sahin DY. et al. Association of Mean Platelet Volume and Preand Postinterventional Flow With Infarct-Related Artery in ST-Segment Elevation Myocardial Infarction. Angiology 2013; 64: 440-446.
• 33 Estevez-Loureiro R, Salgado-Fernandez J, Marzoa-Rivas R. et al. Mean platelet volume predicts patency of the infarct-related artery before mechanical reperfusion and short-term mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2009; 124: 536-540.
• 34 Ki YJP, Ha S, Choi SI. et al. Usefulness of mean platelet volume as a biomarker for long-term clinical outcomes after percutaneous coronary intervention in Korean cohort: A comparable and additive predictive value to high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide. Platelets 2014; 25: 427-432.
• 35 Pereg D, Berlin T, Mosseri M. Mean platelet volume on admission correlates with impaired response to thrombolysis in patients with ST-elevation myocardial infarction. Platelets 2010; 21: 117-121.
• 36 Rechcński TJ, Foryś A, Krzemińska-Pakula J. et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardiol J 2013; 20: 491-498.
• 37 Taglieri N, Saia F, Rapezzi C. et al. Prognostic significance of mean platelet volume on admission in an unselected cohort of patients with non ST-segment elevation acute coronary syndrome. J Thromb Thrombolysis 2011; 106: 132-140.
• 38 Vrsalovic M, Pintaric H, Babic Z. et al. Impact of admission anemia, C-reactive protein and mean platelet volume on short term mortality in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Clin Biochem 2012; 45: 1506-1509.
• 39 Avci A, Boyaci A, Cagli K. et al. Influence of haematological parameters before coronary angioplasty on subsequent restenosis. Acta Cardiol 2004; 59: 263-268.
• 40 Huczek Z, Kochman J, Filipiak KJ. et al. Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 46: 284-290.
• 41 Eisen AB, Assali T, Kornowski A. et al. Mean platelet volume as a predictor for long-term outcome after percutaneous coronary intervention. J Thromb Thrombolysis 2013; 36: 469-474.
• 42 Goncalves SC, Labinaz M, Le May M. et al. Usefulness of mean platelet volume as a biomarker for long-term outcomes after percutaneous coronary intervention. Am J Cardiol 2011; 107: 204-209.
• 43 Liu Q, Wang T, Chen R. et al. Mean platelet volume predicts left descending artery occlusion in patients with non-ST-elevation myocardial infarction. Platelets 2014; 25: 246-251.
• 44 Vakili H, Kowsari R, Namazi MH. et al. Could mean platelet volume predicts impaired reperfusion and in-hospital major adverse cardiovascular event in patients with primary percutaneous coronary intervention after ST-elevation myocardial infarction?. J Tehran Heart Cent 2009; 04: 17-23.
• 45 Wan ZFZ, Xue D, Wu JH. et al. Combination of mean platelet volume and the GRACE risk score better predicts future cardiovascular events in patients with acute coronary syndrome. Platelets 2014; 25: 447-451.
• 46 Yang A, Pizzulli L, Luderitz B. Mean platelet volume as marker of restenosis after percutaneous transluminal coronary angioplasty in patients with stable and unstable angina pectoris. Thromb Res 2006; 117: 371-377.
• 47 Martin JF, Trowbridge EA, Salmon G. et al. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. Thromb Res 1983; 32: 443-460.
• 48 Jakubowski JA, Thompson CB, Vaillancourt R. et al. Arachidonic acid metabolism by platelets of differing size. Br J Haematol 1983; 53: 503-511.
• 49 Thompson CB, Eaton KA, Princiotta SM. et al. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982; 50: 509-519.
• 50 Sansanayudh N, Anothaisintawee T, Muntham D. et al. Mean platelet volume and coronary artery disease: a systematic review and meta-analysis. Int J Cardiol 2014; 175: 433-440.
• 51 Turgutalp K, Ozhan O, Akbay E. et al. Mean platelet volume and related factors in patients at different stages of diabetic nephropathy: a preliminary study. Clin Appl Thromb Hemost 2014; 20: 190-195.
• 52 Shah B, Sha D, Xie D. et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999–2004. Diabetes Care 2012; 35: 1074-1078.
• 53 Papanas N, Symeonidis G, Maltezos E. et al. Mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2004; 15: 475-478.
• 54 Ntaios G, Gurer O, Faouzi M. et al. Hypertension is an independent predictor of mean platelet volume in patients with acute ischaemic stroke. Intern Med J 2011; 41: 691-695.
• 55 Nadar SK, Blann AD, Kamath S. et al. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol 2004; 44: 415-422.
• 56 Cao X, Xie X, Zhou J. et al. Increased platelet volume in a general population with prehypertension: a cross-sectional study of 80 545 participants from China. Hypertens Res 2012; 35: 903-908.
• 57 Lance MD, van Oerle R, Henskens YM. et al. Do we need time adjusted mean platelet volume measurements?. Lab Hematol 2010; 16: 28-31.
• 58 Bath PM. The routine measurement of platelet size using sodium citrate alone as the anticoagulant. J Thromb Haemost 1993; 70: 687-690.
• 59 Grove EL, Hvas AM, Mortensen SB. et al. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011; 09: 185-191.
• 60 Guthikonda S, Lev EI, Patel R. et al. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007; 05: 490-496.
• 61 Guthikonda S, Alviar CL, Vaduganathan M. et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
• 62 Cesari F, Marcucci R, Caporale R. et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2008; 99: 930-935.
• 63 Lippi G, Meschi T, Borghi L. Mean platelet volume increases with aging in a large population study. Thromb Res 2012; 129: e159-160.
• 64 Shimodaira M, Niwa T, Nakajima K. et al. Gender differences in the relationship between serum uric acid and mean platelet volume in a Japanese general population. Platelets 2014; 25: 202-206.
• 65 Hekimsoy Z, Payzin B, Ornek T. et al. Mean platelet volume in Type 2 diabetic patients. J Diabetes Complications 2004; 18: 173-176.
• 66 Yarlioglues M, Ardic I, Dogdu O. et al. The acute effects of passive smoking on mean platelet volume in healthy volunteers. Angiology 2012; 63: 353-357.
• 67 Arslan E, Yakar T, Yavasoglu I. The effect of smoking on mean platelet volume and lipid profile in young male subjects. Anadolu Kardiyol Derg 2008; 08: 422-425.
• 68 Gasparyan AY, Ayvazyan L, Mikhailidis DP. et al. Mean platelet volume: A link between thrombosis and inflammation?. Curr Pharm Des 2011; 17: 47-58.
• 69 Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009; 101: 151-156.
• 70 Martin JF, Kristensen SD, Mathur A. et al. The causal role of megakaryocyte-platelet hyperactivity in acute coronary syndromes. Nat Rev Cardiol 2012; 09: 658-670.